All In Biotech

Drug Trial Radar · NCT07128888

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

A Study to Evaluate the Effect of GZR18 Injection on Gastric Emptying and Its Drug-Drug Interactions With Digoxin, Rosuvastatin Calcium and Warfarin Sodium in Obese or Overweight Subjects

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Sep 24, 2025

Primary completion

Apr 13, 2026

Study completion Apr 13, 2026

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of GZR18 Injection on gastric emptying and the effect of repeated SC injections of GZR18 Injection on the pharmacokinetics of oral digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets. A total of 60 obese or overweight subjects are planned to be enrolled, with no less than one-quarter of the subjects from either gender. The study duration for each subject in this study is approximately 26 weeks: including a screening period of up to 4 weeks (W-28 to D-1), single-drug administration and dose escalation stages of 16 weeks (W1D1 to W16D7) and the combined drug administration stage of 6 weeks (W17D1 to W23D1)

Conditions

  • Obesity or Overweight

Interventions

  • GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tabletsDrug

    GZR18 injection: 3 mg-36 mg,16 weeks; Warfarin Sodium Tablets:2.5mg,twice; Rosuvastatin Calcium Tablets:10mg,twice; Digoxin Tablets:0.25mg,twice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax:Maximum plasma concentrationTime frame: through study completion,up to 16 weeks
  2. AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.Time frame: through study completion,up to 16 weeks
  3. AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose.Time frame: through study completion,up to 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Study site 01

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.